• SB202190 (FHPI) for Reliable p38 Assays

  2026-08-20

  This scenario-based guide explains how SB202190 (FHPI), SKU A1632, can support reproducible p38 MAPK inhibition studies in viability, proliferation, inflammation, and cancer models. It connects compound handling, assay optimization, assembloid interpretation, and practical vendor selection to documented biochemical and formulation data.

• Degarelix Acetate: Assay Design Beyond Potency

  2026-08-19

  Degarelix acetate is a selective GnRH receptor antagonist used to study pituitary hormone regulation and prostate cancer biology. This guide connects receptor pharmacology with peptide aggregation, showing how sample quality and assay design can determine whether an apparent potency result is biologically meaningful.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-08-18

  Anlotinib hydrochloride is a practical multi-target tyrosine kinase inhibitor for linking endothelial phenotypes with VEGFR2, PDGFRβ, FGFR1, and ERK pathway readouts. This workflow-focused guide shows how to build reproducible migration, tube-formation, signaling, and translational cancer research assays while avoiding common dose, timing, and viability confounders.

• Nintedanib (BIBF 1120) Research Workflows

  2026-08-18

  Nintedanib (BIBF 1120) enables mechanism-driven studies of VEGFR, FGFR, and PDGFR signaling in cancer, angiogenesis, and fibrosis models. This guide translates ATRX-stratified glioma findings into practical dosing, combination, assay-selection, and troubleshooting workflows.

• Chlorpromazine: A Rigorous Assay Design Guide

  2026-08-17

  Chlorpromazine is more than a dopamine D2 receptor antagonist: it is a useful anchor for separating receptor pharmacology from cell-specific assay behavior. This guide connects chlorpromazine hydrochloride research with new lessons from hepatic nanoparticle uptake studies while defining practical controls and limitations.

• Phenothiazines Boost Macrophage Antibacterial Activity

  2026-08-17

  Qiu and colleagues show that phenothiazines can strengthen macrophage control of intracellular bacteria by coordinating lysosomal activity, autophagy, and reactive oxygen species. The study supports a host-directed antibacterial strategy and provides a mechanistic framework for testing phenothiazine-class compounds without assuming that their effects arise from direct bacterial killing.

• EZ Cap Cy5 Firefly Luciferase mRNA Guide

  2026-08-16

  Turn one reporter transcript into two complementary measurements: Cy5 reveals where mRNA travels, while Firefly luciferase reports productive expression. This workflow guide covers delivery optimization, formulation-aware controls, imaging, and troubleshooting for reliable mammalian and preclinical studies.

• BHPF–GPER Binding and Neuroblastoma Apoptosis

  2026-08-15

  The reference study identifies fluorene-9-bisphenol (BHPF) as a direct functional inhibitor of GPER1, also called GPR30, rather than simply an estrogen-like contaminant. By combining molecular dynamics, receptor editing, calcium signaling, cytotoxicity, and gene-expression assays, it connects specific receptor residues with disrupted signaling and neuroblastoma cell injury.

• Cathepsin S in Lymphoma Antigen Processing

  2026-08-15

  Dheilly et al. identify cathepsin S as an immune-regulatory vulnerability in follicular lymphoma, linking CTSS overexpression and the recurrent Y132D mutation to altered antigen processing and tumor–T cell communication. The study shows that reducing CTSS activity can weaken CD4+ T follicular helper support while diversifying tumor antigens and promoting CD8+ T cell responses, providing a mechanistic framework for cathepsin inhibition in lymphoma research.

• Sodium Dicloxacillin Monohydrate in MSSA Assays

  2026-08-14

  Sodium dicloxacillin monohydrate is a research tool for dissecting β-lactam activity against MSSA across extracellular and intracellular environments. This guide translates landmark PK/PD findings into practical assay design, interpretation, and reproducibility decisions.

• Ceftolozane Sulfate Workflows for PK/PD Research

  2026-08-14

  Build more informative antibacterial studies by linking ceftolozane MIC values with time-kill behavior, renal-clearance scenarios, and translational PK/PD endpoints. This workflow shows how Ceftolozane sulfate can support susceptibility testing, resistant-pathogen profiling, and neutropenic mouse thigh infection model design while highlighting practical sources of assay variability.

• Temafloxacin Activity Against Gram-Negative Bacteria

  2026-08-13

  Hardy’s review synthesizes comparative in vitro data showing that temafloxacin was highly active against many respiratory, sexually transmitted, enteric, and other Gram-negative pathogens, while its activity against Pseudomonas aeruginosa was weaker than ciprofloxacin. The paper’s principal practical contribution is a structured interpretation of MIC data across organism groups and testing systems, providing a useful framework for antimicrobial spectrum analysis.

• Ertapenem Sodium Salt as a Resistance Probe

  2026-08-13

  Ertapenem sodium salt can do more than define susceptibility: it can anchor a phenotype-to-genotype workflow for antibiotic resistance research. This article connects ertapenem exposure, assay controls, plasmid mobility, and carbapenemase surveillance without conflating clinical pharmacology with laboratory interpretation.

• Measuring Drug Response in Cancer Beyond Viability

  2026-08-12

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth arrest and cell death are related but non-equivalent drug-response dimensions. The framework supports more interpretable cancer pharmacology by aligning endpoint definitions, timing, and orthogonal measurements before comparing compounds or models.

• NF 449 for Selective P2X1 Platelet Studies

  2026-08-12

  NF 449 is a high-potency purinergic receptor antagonist for separating P2X1-dependent platelet signaling from broader purinergic effects. This guide converts its receptor selectivity into practical concentration-response, aggregation, thrombosis-modeling, and troubleshooting workflows.

446 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page